Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human prostate-specific membrane antigen plasmid DNA vaccine
- Development stage
- Phase 1
- Lead developer
- Inovio Pharmaceuticals
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies
- Administration
- Intramuscular
01
Overview
A human prostate-specific membrane antigen plasmid DNA vaccine is a therapeutic cancer vaccine consisting of a plasmid encoding the full-length human prostate-specific membrane antigen (PSMA). Upon administration, the encoded PSMA protein is expressed in host cells, stimulating an immune response—primarily T-cell mediated—against cells expressing PSMA. This approach aims to induce both antibody and cytotoxic T-cell responses targeting prostate cancer cells that overexpress PSMA. The primary indication for this investigational therapy is recurrent or advanced prostate cancer. Clinical trials have demonstrated that such vaccines can elicit immunological responses and are generally well tolerated, with most side effects being mild and related to injection site reactions or flu-like symptoms[2][5][6].
- Other names
- human PSMA plasmid DNA vaccinePSMA DNA vaccine
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on human prostate-specific membrane antigen plasmid DNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human prostate-specific membrane antigen plasmid DNA vaccine.